Searched for
CIPLA STEADY QUARTER
Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Ahead of Market: 10 things that will decide stock market action on FridayBSE Sensex and Nifty 50 extended gains for a second session, led by banking, metal and pharma stocks despite IT weakness. Analysts flagged ...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...
- Pharma companies set for strong performance in March 2025 quarter amid earning weaknessSun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic thera...
- Cipla shares surge over 6% post Q4 results. Should you buy or sell?Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.
- Stocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata SteelConsumer discretionary major Titan Co saw 22% revenue growth for the third quarter ended December. The growth was broad-based as most of th...
- Pharma Q2 Preview: Cipla to see steady quarter; higher profit and revenue growth for Dr Reddy'sCipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on...
- Cipla surges 10% with rise in price targetsThe average price target of the 28 analysts, whose ratings and price targets that have been compiled by Bloomberg, is ₹1,161. The stock clo...
- Buy Cipla, target price Rs 1260: Axis SecuritiesCipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 86522.68 Crore) operating in Pharmaceuticals sector.
- Most brokerages bullish on Cipla; cite US, local market growth potentialMost brokerages maintained a bullish view on Cipla citing the pharmaceutical major's healthy pipeline of product launches in the United Sta...
- Cipla Q2 results: Net profit rises 8% to Rs 712 cr; meets D-Street estimateRevenues for the quarter rose 10.3 per cent YoY to Rs 5,485.84 crore compared with Rs 4,972.58 crore in the same quarter last year.
- Lupin, Cipla numbers raise hopes of a recoveryWe are pleased with the robust all-round performance in our key markets, said Lupin MD.
- Buy Cipla; target Rs 605: HDFC SecuritiesBuy Cipla Ltd. at a price target of Rs 605.
- Centrum cuts target price for CiplaCipla's revenues during Q2FY19 declined 2% YoY while the margin was down by 220 bps.
- CLSA upgrades Cipla to 'Buy' from 'Outperform'; raises target priceCLSA raised the target price of Cipla to Rs 655 from Rs 525 post Q1.
- New business model may put pressure on Cipla’s earnings in short termUnless the company significantly underperforms in the current quarter to March, it is likely to exceed the targetted growth.
- Cipla: Focus on exports critical to swing in future surprisesCipla reported better-than-expected earnings for the quarter ended December 2009 on account of a drop in other expenses and marginally lowe...
- Pharma hopes to reap from new acquisitions, local salesPharmaceutical companies are seen posting a 40-50% growth in earnings for the July-September quarter from the same period last year, driven...
Load More
